UNSPSC 51172132: Moxaverine or moxaverine hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C20H21NO2 and C20H21NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers P3P08Y1XJ4, chemically known as 3-ethyl-1-benzyl-6,7-dimethoxyisoquinoline but generally known as moxaverine, which bears US NIH Compound Identifier 70882. European Medicines Agency schedules Moxaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB09082MIG and SUB03341MIG.

UNSPSC 51172132 Moxaverine or moxaverine hydrochloride is a Commodity code that covers a specific pharmaceutical active ingredient, yet the recent state and local solicitations tagged under it reflect broader drug testing and generic pharmaceutical procurement rather than moxaverine-specific buying. State and local governments are procuring specimen collection and drug testing services (including immunoassay screening and confirmatory testing via LC/MS/MS or GC/MS), generic multi-source pharmaceuticals distributed through authorized wholesalers, and exploratory contracting for direct-to-manufacturer prescription programs. The mix of issuing bodies includes county criminal justice departments (Collin County Community Supervision and Corrections), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The scope of actual work diverges significantly from the code's chemical specificity—procurement activity centers on drug screening service delivery, pharmaceutical distribution logistics, and pharmacy benefit program strategy rather than procurement of moxaverine itself.

Recent activity spans Texas and Minnesota, with Collin County's RFP for offender specimen collection and drug testing services (due July 23, 2026, estimated value $600,000, two-year term with three optional one-year renewals) representing immediate county-level demand; the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescriptions (April 3, 2026 response deadline) signals state-level exploration of pharmacy contracting models; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (proposals due March 26, 2026, effective July 1, 2026, serving state and local facilities across participating jurisdictions including Oregon) demonstrates multistate cooperative framework activity. The code shows limited recent activity directly tied to moxaverine procurement, suggesting either narrow market application or potential UNSPSC tagging misalignment with the actual pharmaceutical and testing services being solicited.